Jianping Yin

Jianping Yin

Auto-generated profile, based on publicly available information

Jianping Yin

Department of Structural Biology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
TSTianhe Sun
Tianhe Sun
ZHZhiyu Huang
Zhiyu Huang
WLWei-Ching Liang
Wei-Ching Liang
JYJianping Yin
Jianping Yin
WLWei Yu Lin
Wei Yu Lin
JAJoseph R. Arron
Joseph R. Arron
TGFβ2 and TGFβ3 isoforms are activated via unique mechanisms and are associated with fibrosis in human diseases.

28 November 2019 in mAbs
Verified
Journal Article
Open access
CTCholpon Tilegenova
Cholpon Tilegenova
SISaeed Izadi
Saeed Izadi
JYJianping Yin
Jianping Yin
CHChristine S. Huang
Christine S. Huang
JWJiansheng Wu
Jiansheng Wu
PCPaul J. Carter
Paul J. Carter
Some antibodies exhibit elevated viscosity at high concentrations, making them poorly suited for therapeutic applications requiring administration by injection such as subcutaneous or ocular delivery. Here we studied an anti-IL-13/IL-17 bispecific IgG4 antibody, which has anomalously high viscosity compared to its parent monospecific antibodies. The viscosity of the bispecific IgG4 in solution was decreased by only ~30% in the presence of NaCl, suggesting electrostatic interactions are insufficient to fully explain the drivers of viscosity. Intriguingly, addition of arginine-HCl reduced the viscosity of the bispecific IgG4 by ~50% to its parent IgG level. These data suggest that beyond electrostatics, additional types of interactions such as cation-π and/or π-π may contribute to high viscosity more significantly than previously understood. Molecular dynamics simulations of antibody fragments in the mixed solution of free arginine and explicit water were conducted to identify hotspots involved in self-interactions. Exposed surface aromatic amino acids displayed an increased number of contacts with arginine. Mutagenesis of the majority of aromatic residues pinpointed by molecular dynamics simulations effectively decreased the solution’s viscosity when tested experimentally. This mutational method to reduce the viscosity of a bispecific antibody was extended to a monospecific anti-GCGR IgG1 antibody with elevated viscosity. In all cases, point mutants were readily identified that both reduced viscosity and retained antigen-binding affinity. These studies demonstrate a new approach to mitigate high viscosity of some antibodies by mutagenesis of surface-exposed aromatic residues on complementarity-determining regions that may facilitate some clinical applications.

14 December 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
JCJoseph Chavarria-Smith
Joseph Chavarria-Smith
CCCecilia P.C. Chiu
Cecilia P.C. Chiu
JJJanet K. Jackman
Janet K. Jackman
JYJianping Yin
Jianping Yin
JZJuan Zhang
Juan Zhang
TYTangsheng Yi
Tangsheng Yi
The epidermis is a barrier that prevents water loss while keeping harmful substances from penetrating the host. The impermeable cornified layer of the stratum corneum is maintained by balancing continuous turnover driven by epidermal basal cell proliferation, suprabasal cell differentiation, and corneal shedding. The epidermal desquamation process is tightly regulated by balance of the activities of serine proteases of the Kallikrein-related peptidases (KLK) family and their cognate inhibitor lymphoepithelial Kazal type–related inhibitor (LEKTI), which is encoded by the serine peptidase inhibitor Kazal type 5 gene. Imbalance of proteolytic activity caused by a deficiency of LEKTI leads to excessive desquamation due to increased activities of KLK5, KLK7, and KLK14 and results in Netherton syndrome (NS), a debilitating condition with an unmet clinical need. Increased activity of KLKs may also be pathological in other dermatoses such as atopic dermatitis (AD). Here, we describe the discovery of inhibitory antibodies against murine KLK5 and KLK7 that could compensate for the deficiency of LEKTI in NS. These antibodies are protective in mouse models of NS and AD and, when combined, promote improved skin barrier integrity and reduced inflammation. To translate these findings, we engineered a humanized bispecific antibody capable of potent inhibition of human KLK5 and KLK7. A crystal structure of KLK5 bound to the inhibitory Fab revealed that the antibody binds distal to its active site and uses a relatively unappreciated allosteric inhibition mechanism. Treatment with the bispecific anti-KLK5/7 antibody represents a promising therapy for clinical development in NS and other inflammatory dermatoses.